Deferasirox 100mg Tablets

Deferasirox 100mg Tablets is a highly effective oral iron-chelating agent designed to manage chronic iron overload in patients who require frequent blood transfusions. In conditions like Thalassemia or Myelodysplastic Syndromes, the body lacks a natural mechanism to excrete the excess iron gained from transfused red blood cells. This medication works as a tridentate chelator, meaning it has a high and specific affinity for trivalent (ferric) iron. Each molecule of Deferasirox binds to iron in a 2:1 ratio, forming a stable, non-toxic complex that is then excreted primarily through the feces via the bile. By removing this “free iron” from the blood and tissues, the drug prevents iron-mediated oxidative damage to vital organs such as the heart, liver, and endocrine glands. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for long-term iron management, offering a convenient oral alternative to painful, multi-hour infusions of older chelators.

The 100mg tablet is the essential unit for precise dosage titration and is particularly valuable for pediatric patients or those requiring small incremental adjustments. Unlike older dispersible formulations, modern film-coated tablets can be swallowed whole, providing more consistent absorption and improved gastrointestinal tolerability. The 100mg strength allows clinicians to fine-tune the daily dose based on the patient’s body weight and serum ferritin levels, ensuring that the rate of iron removal stays in balance with the rate of iron intake from transfusions.

Indications and Uses of Deferasirox 100mg Tablets

Deferasirox 100mg Tablets is commonly prescribed for the specialized management of the following conditions:

• Transfusional Iron Overload: It is indicated for the treatment of chronic iron overload due to blood transfusions (hemosiderosis) in adult and pediatric patients (aged 2 years and older).
• Non-Transfusion-Dependent Thalassemia (NTDT): The medication is used for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older who have a liver iron concentration (LIC) of at least 5 mg Fe/g dry weight.

Key Features of Deferasirox 100mg Tablets

• High Specificity for Iron: The primary feature of Deferasirox 100mg Tablets is its selective binding to ferric iron, sparing other essential minerals like zinc or copper.
• Oral Convenience: It replaces the need for burdensome, 8-to-12-hour subcutaneous infusions of desferrioxamine, significantly enhancing patient quality of life.
• 24-Hour Coverage: Its long half-life allows for once-daily dosing, providing continuous chelation and protection against iron-induced organ damage.
• Pediatric Friendly: The 100mg size facilitates accurate dosing for small children whose weight-based requirements are lower.
• Improved Bioavailability: Modern film-coated tablets offer more predictable blood levels compared to older “Exjade” dispersible versions.

Storage for Deferasirox 100mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Deferasirox 100mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original blister pack or bottle, protected from moisture and light. Do not remove the desiccant from the bottle if one is present. For maximum safety, always store Deferasirox 100mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets.

Safety Warnings for Deferasirox 100mg Tablets

The administration of Deferasirox 100mg Tablets is associated with serious Black Box Warnings regarding kidney and liver function. Nephrotoxicity (kidney damage) and Hepatic Failure have occurred, sometimes with fatal outcomes. Serum creatinine must be checked twice before starting therapy and monitored monthly thereafter. Liver function tests (ALT, AST, Bilirubin) must also be checked monthly.

Gastrointestinal Hemorrhage: Severe, sometimes fatal, stomach or intestinal bleeding has been reported, especially in elderly patients or those with low platelet counts. Cytopenias: It can cause severe decreases in blood counts (leukopenia, thrombocytopenia, anemia); regular blood monitoring is required.

Vision and Hearing: It may cause cataracts or hearing loss; baseline and annual eye and ear exams are recommended. Deferasirox 100mg Tablets can cause fetal harm (Pregnancy Category C/D); effective contraception is mandatory. By strictly following these professional guidelines and monitoring kidney and liver labs, healthcare providers can safely maximize the organ-protective benefits of Deferasirox 100mg Tablets.